SCHEMBL4188055

SCHEMBL4188055

COc1ccccc1CC(=O)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
LMNA P02545 4/20 0.49
TSHR P16473 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 1/20 0.49
TP53 P04637 3/20 0.43
POLB P06746 2/20 0.43
TRPV1 Q8NER1 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 1/20 0.39
PPARG P37231 1/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190805 0.92 TP53 (0.43) MAPTLMNATSHRSMN1; SMN2HTT
SCHEMBL4182610 0.89 ADORA2A (0.43) MAPTLMNATSHRSMN1; SMN2HTT
SCHEMBL4182715 0.89 TP53 (0.45) MAPTLMNASMN1; SMN2HTTTP53
SCHEMBL4187214 0.88 POLB (0.45) MAPTLMNASMN1; SMN2HTTTP53
SCHEMBL2409603 0.88 FEN1 (0.43) MAPTPOLBKMT2AMEN1PDE4B
SCHEMBL4185694 0.87 TP53 (0.47) MAPTLMNASMN1; SMN2HTTTP53
SCHEMBL4187658 0.85 POLB (0.47) MAPTLMNASMN1; SMN2TP53POLB
SCHEMBL4182553 0.85 MAPT (0.48) MAPTLMNASMN1; SMN2HTTTP53
SCHEMBL4183574 0.84 TP53 (0.44) MAPTLMNASMN1; SMN2HTTTP53
SCHEMBL4195071 0.84 CNR2 (0.44) MAPTLMNASMN1; SMN2TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A MAPT 4865/4885LMNA 3446/4885TSHR 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.